Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Thank you for choosing ACROBiosystems. Would you rate our product and service? Thank you for choosing ACROBiosystems. Would you rate our product and service?
Here come GMP Grade Cytokines!Free Sample is available! Here come GMP Grade Cytokines!Free Sample is available!
Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
DLL3 mAb - 01 | Lead | Solid Tumor | Small cell lung cancer |
5e5 of anti-DLL3 CAR-293 cells were stained with 100 μL of 1 μg/mL of Alexa Fluor 647-Labeled Human DLL3 Protein, His Tag (Cat. No. DL3-HA2H3) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). Alexa 647 signal was used to evaluate the binding activity (QC tested).
Immobilized Biotinylated Cynomolgus DLL3, His,Avitag (Cat. No. DL3-C82E9) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-DLL3 Antibody (specific Binding DSL of DLL3), Human IgG1 with a linear range of 0.1-1 ng/mL (QC tested).
The purity of Biotinylated Human DLL3, His,Avitag (Cat. No. DL3-H82E4) is more than 90% and the molecular weight of this protein is around 50-75 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
89Zr-DFO-SC16.56 | 89Zr-DFO-SC16.56 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Small Cell Lung Carcinoma | Details |
AMG-119 | AMG-119 | Amgen Inc | Details | ||
HPN-328 | HPN-328 | Harpoon Therapeutics | Details | ||
QLS-31904 | QLS31904; QLS-31904 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours | Details |
DLL3-CAR-NK cells Therapy(Tianjin Medical University Cancer Institute and Hospital) | DLL3-CAR-NK cells | Phase 1 Clinical | Tianjin Medical University Cancer Institute And Hospital | Small Cell Lung Carcinoma | Details |
PT-217 | PT-217 | Phase 1 Clinical | Phanes Therapeutics Inc | Small Cell Lung Carcinoma; Carcinoma, Neuroendocrine | Details |
BI-764532 | BI-764532 | Phase 1 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Small Cell Lung Carcinoma; Neoplasms | Details |
OBT620 | OBT620 | Phase 1 Clinical | Boehringer Ingelheim Gmbh, Oxford Biotherapeutics Ltd | Small Cell Lung Carcinoma | Details |
Tarlatamab | AMG-757 | Phase 2 Clinical | Amgen Inc | Small Cell Lung Carcinoma; Prostatic Neoplasms | Details |
LB-2102(Legend Biotechnology) | LB-2102 | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Small Cell Lung Carcinoma | Details |
Rovalpituzumab tesirine | SC-0002; SC0001SCX; SC16LD6.5; SC0001-SCX; P256HB60FF | Phase 1 Clinical | Stemcentrx Inc, Abbvie Inc | Solid tumours; Small Cell Lung Carcinoma; Glioblastoma; Neoplasms; Prostatic Neoplasms; Medullary thyroid cancer (MTC); Carcinoma, Neuroendocrine; Melanoma | Details |
This web search service is supported by Google Inc.